Full Press Release Details
MARINA DEL REY, Calif. , May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced an oral presentation on the company's recently completed Phase 1b /2a SWARM- P.a. clinical trial at the 6 th World Conference on Targeting Phage Therapy, which is being held June 1-2, 2023 , in Paris .
The SWARM- P.a. trial was a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study that evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Armata's lead clinical bacteriophage candidate, AP-PA02, in patients with cystic fibrosis and chronic pulmonary Pseudomonas aeruginosa infection. Armata announced positive topline data from the trial in March 2023 .
Details of the presentation are as follows:
| Title: | Safety, Pharmacokinetics, and Antibacterial Activity of AP-PA02 Multi-phage Cocktail in Patients with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa Infection (SWARM- P.a. Clinical Trial) |
| Presenter: | Mina Pastagia, MD, MS, Chief Medical Officer, Armata Pharmaceuticals |
| Session: | Session 5 - Phage Therapy: Towards Amplification and Innovation |
| Date: | June 2, 2023 |
| Time: | 10:50 a.m. CEST (4:50 a.m. EDT) |
For more information: https://phagetherapy-site.com/
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Media Contacts:
At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. [email protected] 310-665-2928 x234
Investor Relations:
Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.